Study #2024-0003
Phase 1, first-in-human, dose escalation study of JNJ-79635322, a trispecific antibody, in participants with relapsed or refractory multiple myeloma or previously treated AL amyloidosis
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-79635322
Description
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Study phase:
Phase I
Physician name:
Hans Lee
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-494-1356
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.